Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAPOR (GETUG T06) – Personalized treatment for poor-prognosis non-seminomatous germ-cell tumors
2021-006638-38Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Mar 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide and carboplatin in non-seminomatous germ cell tumor (NSGCT), sponsored by Gustave Roussy. Primary endpoint: progression-free survival. Started Mar 2022; status: active.
02
Drugs
etoposidecarboplatin
03
Conditions
non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on 2021-006638-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006638-38.